Jasbir Seehra - 09 Jun 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Executive Officer, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
09 Jun 2022
Net transactions value
+$1,500
Form type
4
Filing time
10 Jun 2022, 16:12:01 UTC
Previous filing
25 Jan 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1,500 +5,000 +2.1% $0.3000* 248,856 09 Jun 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -5,000 -36% $0.000000 8,822 09 Jun 2022 Common Stock 5,000 $0.3000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.